158 related articles for article (PubMed ID: 31977380)
1. Genomic Strategies to Personalize Use of Androgen Deprivation Therapy With Radiotherapy.
Glicksman RM; Berlin A
Cancer J; 2020; 26(1):13-20. PubMed ID: 31977380
[TBL] [Abstract][Full Text] [Related]
2. Next Generation of Androgen Deprivation Therapy Combined With Radiotherapy for N0 M0 Prostate Cancer.
Barata P; Layton J; Lewis B; Sartor O
Cancer J; 2020; 26(1):21-28. PubMed ID: 31977381
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Approaches Prior To Radical Prostatectomy.
Ryan ST; Patel DN; Parsons JK; McKay RR
Cancer J; 2020; 26(1):2-12. PubMed ID: 31977379
[TBL] [Abstract][Full Text] [Related]
4. Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: Yes.
Palapattu GS
J Urol; 2017 Aug; 198(2):265-266. PubMed ID: 28629664
[No Abstract] [Full Text] [Related]
5. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
[TBL] [Abstract][Full Text] [Related]
6. Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: No.
Punnen S; Parekh DJ
J Urol; 2017 Aug; 198(2):266-267. PubMed ID: 28629663
[No Abstract] [Full Text] [Related]
7. Health economic impact of a biopsy-based cell cycle gene expression assay in localized prostate cancer.
Gustavsen G; Taylor K; Cole D; Gullet L; Lewine N
Future Oncol; 2020 Dec; 16(36):3061-3074. PubMed ID: 32902306
[No Abstract] [Full Text] [Related]
8. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
9. Clinically Lymph Node Positive Prostate Cancer: At the Intersection of Focal and Systemic Disease Control.
Reichert ZR; Dess RT
Cancer J; 2020; 26(1):53-57. PubMed ID: 31977386
[TBL] [Abstract][Full Text] [Related]
10. Advanced Prostate Cancer: Treatment Advances and Future Directions.
Swami U; McFarland TR; Nussenzveig R; Agarwal N
Trends Cancer; 2020 Aug; 6(8):702-715. PubMed ID: 32534790
[TBL] [Abstract][Full Text] [Related]
11. Combined hormone therapy and radiation therapy for locally advanced prostate cancer.
Bolla M; Laramas M;
Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e30-4. PubMed ID: 21144766
[TBL] [Abstract][Full Text] [Related]
12. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.
Mason MD; Parulekar WR; Sydes MR; Brundage M; Kirkbride P; Gospodarowicz M; Cowan R; Kostashuk EC; Anderson J; Swanson G; Parmar MK; Hayter C; Jovic G; Hiltz A; Hetherington J; Sathya J; Barber JB; McKenzie M; El-Sharkawi S; Souhami L; Hardman PD; Chen BE; Warde P
J Clin Oncol; 2015 Jul; 33(19):2143-50. PubMed ID: 25691677
[TBL] [Abstract][Full Text] [Related]
13. Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.
Spratt DE; Tward JD
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):899-902. PubMed ID: 32928598
[No Abstract] [Full Text] [Related]
14. Radiotherapy and Hormone Treatment in Prostate Cancer.
Böhmer D; Wirth M; Miller K; Budach V; Heidenreich A; Wiegel T
Dtsch Arztebl Int; 2016 Apr; 113(14):235-41. PubMed ID: 27146591
[TBL] [Abstract][Full Text] [Related]
15. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
16. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
17. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
18. Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer : Statement from the DEGRO working group on prostate cancer.
Beck M; Böhmer D; Aebersold DM; Albrecht C; Flentje M; Ganswindt U; Höcht S; Hölscher T; Müller AC; Niehoff P; Pinkawa M; Sedlmayer F; Zips D; Zschaeck S; Budach V; Wiegel T; Ghadjar P;
Strahlenther Onkol; 2020 Feb; 196(2):109-116. PubMed ID: 31784804
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy and definitive radiotherapy for prostate cancer.
Mendenhall WM; Henderson RH; Hoppe BS; Nichols RC; Mendenhall NP
Am J Clin Oncol; 2013 Oct; 36(5):530-4. PubMed ID: 21694574
[TBL] [Abstract][Full Text] [Related]
20. Genomic tests to guide prostate cancer management following diagnosis.
Colicchia M; Morlacco A; Cheville JC; Karnes RJ
Expert Rev Mol Diagn; 2017 Apr; 17(4):367-377. PubMed ID: 28277880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
